John R. Moore Sells 1,956 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel John R. Moore sold 1,956 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $36,987.96. Following the completion of the transaction, the general counsel now owns 3,252 shares of the company’s stock, valued at $61,495.32. The sale was disclosed in a document filed with the SEC, which is available through this link.

John R. Moore also recently made the following trade(s):

• On Friday, February 9th, John R. Moore sold 8,029 shares of Edgewise Therapeutics stock. The stock was sold at an average price of $20.01, for a total transaction of $160,660.29.
• On Wednesday, February 7th, John R. Moore sold 17,993 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $359,860.00.

Edgewise Therapeutics Stock Up 1.2 %

Edgewise Therapeutics stock opened at $19.52 on Friday. Edgewise Therapeutics, Inc. has a one year low of $5.12 and a one year high of $20.90. The business’s fifty day moving average is $16.90 and its 200 day moving average is $12.73.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). As a group, research analysts anticipate that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current year.

Wall Street Analyst Weigh In

EWTX has been the subject of a number of recent research reports. Royal Bank of Canada lifted their price objective on Edgewise Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, April 22nd. Truist Financial reiterated a “buy” rating and issued a $25.00 price target on shares of Edgewise Therapeutics in a research note on Wednesday, April 17th. Wedbush restated an “outperform” rating and set a $26.00 price objective on shares of Edgewise Therapeutics in a research note on Tuesday, April 16th. Finally, Piper Sandler began coverage on shares of Edgewise Therapeutics in a research note on Thursday, March 7th. They issued an “overweight” rating and a $48.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $31.20.

Hedge Funds Weigh In On Edgewise Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of EWTX. Quantum Private Wealth LLC grew its holdings in shares of Edgewise Therapeutics by 2.4% in the fourth quarter. Quantum Private Wealth LLC now owns 63,219 shares of the company’s stock worth $692,000 after acquiring an additional 1,500 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in shares of Edgewise Therapeutics by 3.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 116,900 shares of the company’s stock valued at $670,000 after purchasing an additional 3,900 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Edgewise Therapeutics by 29.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,833 shares of the company’s stock valued at $228,000 after purchasing an additional 4,785 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Edgewise Therapeutics by 349.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,338 shares of the company’s stock worth $80,000 after purchasing an additional 5,704 shares during the period. Finally, AJOVista LLC purchased a new position in shares of Edgewise Therapeutics in the fourth quarter worth approximately $84,000.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.